Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Multiple Myeloma Melflufen Plasma Cell Myeloma Orphan Drug Relapsed & Relapsed-Refractory Multiple Myeloma peptidase potentiated anti-angiogenic cytotoxicity alkylation peptidase targeting Phase II efficacy studies oncology Ygalo Phase III Relapsed & Relapsed-Refractory Multiple Myeloma Melflufen Peptidase Enhanced Cytotoxics PEnC peptide conjugated alkylator phase 3 phase 1 phase 3 melflufen RRMM Relapsed & Relapsed-Refractory Multiple Myeloma